Seeking Alpha
Seeking Alpha Portfolio App for iPad
Finance
(1)
Market Currents

Peregrine (PPHM) storms 15.6% higher after its bavituximab treatment performed well in a Phase...

  • Wednesday, February 13, 8:58 AM ET
    Peregrine (PPHM) storms 15.6% higher after its bavituximab treatment performed well in a Phase II trial of 70 patients with advanced Stage IV pancreatic cancer. In combination with the gemcitabine chemotherapy, overall tumor response rates were 28% vs 13% with gemcitabine alone. (PR)
Track new comments on this story

This news story has 2 comments:

  •  
    Hmm, 17% up now for improvement of MOS from 5.2 to 5.6 month. Is that even statistically significant? Not sure, just saying. Wishing the best to all pancreas cancer patients.
    13 Feb, 09:10 AM Reply Like
  •  
    Overall survival was the primary endpoint which was only a fraction of a month better than control arm. Ridiculous how this company continues to play with data.
    13 Feb, 09:35 AM Reply Like
LATEST|
TODAY SO FAR|
YESTERDAY
Other date
DJIA (DIA) S&P 500 (SPY)

HEALTHCARE ETFs IN FOCUS

Latest Healthcare Articles
More Latest Articles »